Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2003

View Archived Issues

Spotlight on S-adenosyl-L-methionine (SAMe)

Kyoto Pharmaceutical presents novel glucose- and lipid-lowering agents

Elan and Pharmacia jointly report new series of beta-secretase inhibitors

Novel SGLT-1 inhibitors prepared and tested at Kissei

Mochida researchers identify analgesic agents resistant to metabolic degradation

Permeation enhancers discovered by Allergan scientists

New atrial-selective antiarrhythmic agents covered by Nissan Chemical patent

Yamanouchi reports novel VEGF inhibitors

Mitsubishi Pharma reports novel PARP inhibitors with utility in cerebral infarction

QRX-101 phase II trial in psoriasis cleared to begin

First clinical trial of ACP-103, targeted for treatment-induced dysfunction in Parkinson's disease

G17DT recommended for orphan drug status in E.U.

Velcade NDA submitted for multiple myeloma

Positive findings for Nastech's intranasal sumatriptan

Theratechnologies acquires new peptide with potential application in diabetes

European launch of Cialis under way

PT-141 effective in ED patients who fail to respond to Viagra

Arestin approved in Sweden

Amgen submits sBLA for Enbrel in ankylosing spondylitis

Geron reports new data on hematopoietic cell production from hESCs

Geron refocuses resources

New treatment option for COPD nearing approval in Europe

Divalproex sodium reported safer than olanzapine in bipolar disorder

Two courses of alefacept evaluated in patients with chronic plaque psoriasis

Antiinflammatory effects of omega-3 fatty acids

Teijin and Kyorin to form new company

Reduced parenteral nutrition requirement with rhGH and glutamine in short bowel syndrome

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026